|Bid||3.85 x 900|
|Ask||4.98 x 1400|
|Day's Range||4.1900 - 4.4600|
|52 Week Range||2.6600 - 29.2500|
|Beta (3Y Monthly)||3.81|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 9, 2018 - Aug 11, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.50|
General counsel for four local public companies signed a letter expressing disappointment in the diversity of law-firm leaders. Those four companies have three female board members, combined.
CAMBRIDGE, Mass., Jan. 03, 2019 -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies.
CAMBRIDGE, Mass., Jan. 02, 2019 -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies.
We at Insider Monkey have gone over 700 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds’ and investors’ portfolio positions as of September 30th. In this article, we look at what those funds think of Jounce Therapeutics, Inc. (NASDAQ:JNCE) based on that […]
NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of 32.35% and 13.50%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Jounce Therapeutics, Inc. (JNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of 62.16% and 55.36%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Jounce Therapeutics, Inc. (NASDAQ: JNCE ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 8:00 AM Eastern ...
LONDON, UK / ACCESSWIRE / July 11, 2018 / If you want a free Stock Review on XON sign up now at www.wallstequities.com/registration. On Tuesday, July 10, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Seven out of nine sectors ended Tuesday's trading session in bullish territories.
As Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) closes at new highs, analysts are gushing over the company’s prospects. What is it about Agios stock that has the experts bullish on the company? Markets speculated that Celgene Corporation (NASDAQ:CELG) would buy Agios or Jounce Therapeutics, Inc. (NASDAQ:JNCE) back in April.